Bellerophon Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2017 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Bellerophon Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2017 to Q1 2023.
  • Bellerophon Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2023 was $4.98M.
  • Bellerophon Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$40K.
  • Bellerophon Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2020 was $57.6M, a 833% increase from 2019.
  • Bellerophon Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2019 was $6.17M, a 3615% increase from 2018.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $4.98M +$4.98M Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q1 2022 $0 $0 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q1 2021 $0 -$3.06M -100% Jan 1, 2021 Mar 31, 2021 10-Q 2021-05-11
Q1 2020 $3.06M -$3.32M -52% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q1 2019 $6.37M +$6.4M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q1 2018 -$28K -$313K -110% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q1 2017 $285K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.